These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

635 related items for PubMed ID: 1379664

  • 1. Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate.
    Amrein PC, Fabian RL.
    Laryngoscope; 1992 Aug; 102(8):901-6. PubMed ID: 1379664
    [Abstract] [Full Text] [Related]

  • 2. Alternating combination chemotherapy using cisplatin-bleomycin with sequential methotrexate-5-FU plus leucovorin rescue in patients with head and neck cancer.
    Panasci L, Gravenor D, Black M, Frenkiel S, Margolese R.
    Cancer Treat Rep; 1985 Sep; 69(9):1015-7. PubMed ID: 2411401
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
    Okuno SH, Mailliard JA, Suman VJ, Edmonson JH, Creagan ET, Nair S, Levitt R, Kugler JW.
    Cancer; 2002 Apr 15; 94(8):2224-31. PubMed ID: 12001121
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
    Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Martí JL, Lobo F, Pastor P, Valentí V, Belón J, Sánchez MA, Chaib C, Pallarés C, Antón A, Cervantes A, Paz-Ares L, Cortés-Funes H.
    J Clin Oncol; 2005 Dec 01; 23(34):8636-45. PubMed ID: 16275937
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH, Cheng AL, Hsu C, Yang CH, Lu YS, Lin CC, Bu CF, Yeh KH.
    Anticancer Res; 2002 Dec 01; 22(6B):3621-7. PubMed ID: 12552966
    [Abstract] [Full Text] [Related]

  • 9. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
    Worden FP, Moon J, Samlowski W, Clark JI, Dakhil SR, Williamson S, Urba SG, Ensley J, Hussain MH, Southwest Oncology Group, Head and Neck Working Group.
    Cancer; 2006 Jul 15; 107(2):319-27. PubMed ID: 16779801
    [Abstract] [Full Text] [Related]

  • 10. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
    Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, Forastiere AA, Eastern Cooperative Oncology Group.
    J Clin Oncol; 2005 May 20; 23(15):3562-7. PubMed ID: 15908667
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer.
    Wagenaar HC, Colombo N, Vergote I, Hoctin-Boes G, Zanetta G, Pecorelli S, Lacave AJ, van Hoesel Q, Cervantes A, Bolis G, Namer M, Lhommé C, Guastalla JP, Nooij MA, Poveda A, Scotto di Palumbo V, Vermorken JB.
    Gynecol Oncol; 2001 Jun 20; 81(3):348-54. PubMed ID: 11371121
    [Abstract] [Full Text] [Related]

  • 13. Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience.
    Papadimitrakopoulou VA, Dimery IW, Lee JJ, Perez C, Hong WK, Lippman SM.
    Cancer J Sci Am; 1997 Jun 20; 3(2):92-9. PubMed ID: 9099459
    [Abstract] [Full Text] [Related]

  • 14. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A, Kwong M, DiStasio S, Lekakis L, Kassar M, Sasaki C, Wilson LD, Haffty BG, Son YH, Ross DA, Weinberger PM, Chung GG, Zelterman D, Burtness BA, Cooper DL.
    J Clin Oncol; 2004 Aug 01; 22(15):3061-9. PubMed ID: 15284256
    [Abstract] [Full Text] [Related]

  • 15. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM, Glisson BS, Khuri FR, Ginsberg L, Lawhorn K, Hong WK, Lippman SM.
    Semin Oncol; 1997 Dec 01; 24(6 Suppl 19):S19-33-S19-37. PubMed ID: 9427263
    [Abstract] [Full Text] [Related]

  • 16. Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
    Katori H, Tsukuda M, Taguchi T.
    Cancer Chemother Pharmacol; 2007 May 01; 59(6):789-94. PubMed ID: 17053926
    [Abstract] [Full Text] [Related]

  • 17. A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN).
    Baghi M, Hambek M, Wagenblast J, May A, Gstoettner W, Knecht R.
    Anticancer Res; 2006 May 01; 26(1B):585-90. PubMed ID: 16739325
    [Abstract] [Full Text] [Related]

  • 18. Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck.
    Tsukuda M, Ishitoya J, Matsuda H, Horiuchi C, Taguchi T, Takahashi M, Nishimura G, Kawakami M, Watanabe M, Niho T, Kawano T, Ikeda Y, Sakuma Y, Shiono O, Komatsu M.
    Cancer Chemother Pharmacol; 2010 Sep 01; 66(4):729-36. PubMed ID: 20033810
    [Abstract] [Full Text] [Related]

  • 19. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
    Kiyota N, Tahara M, Kadowaki S, Fuse N, Doi T, Minami H, Ohtsu A.
    Jpn J Clin Oncol; 2009 Apr 01; 39(4):225-30. PubMed ID: 19211574
    [Abstract] [Full Text] [Related]

  • 20. Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma.
    Tsai TL, Chu PY, Tai SK, Wang YF, Yang MH, Wang LW, Lirng JF, Chang SY.
    Jpn J Clin Oncol; 2011 Oct 01; 41(10):1182-93. PubMed ID: 21862506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.